HUE034099T2 - Antimikrobiális tartósítószerek, béta-ciklodextrineket alkalmazó multidózisos formulációk eléréséhez folyékony dózisformák számára - Google Patents

Antimikrobiális tartósítószerek, béta-ciklodextrineket alkalmazó multidózisos formulációk eléréséhez folyékony dózisformák számára Download PDF

Info

Publication number
HUE034099T2
HUE034099T2 HUE05702263A HUE05702263A HUE034099T2 HU E034099 T2 HUE034099 T2 HU E034099T2 HU E05702263 A HUE05702263 A HU E05702263A HU E05702263 A HUE05702263 A HU E05702263A HU E034099 T2 HUE034099 T2 HU E034099T2
Authority
HU
Hungary
Prior art keywords
compound
formula
cyclodextrin
cresol
meta
Prior art date
Application number
HUE05702263A
Other languages
English (en)
Inventor
Roger Christopher Adami
Frederick Pfizer Global R & D David
Julia Ann Wood
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34910697&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE034099(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of HUE034099T2 publication Critical patent/HUE034099T2/hu

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Dermatology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (5)

  1. 8zabsdds*:ii jg&amp;äypöotök i GyógYszerészeti kksiktínény, amely tartalmaz lö trag A.dél í a. kgpietil vegyüldd: 1 .......U 1 1. éx ^...A·,., // \ nnT y \ \-: ::: :/ ^G-/ vagy gyögysztnészesüeg eó<:>gadbaté ózlak ói-72. öuGrt; B/uírobUiiíékr'IGdk-iöáé^jGííí. 3.2-4,2 mgóni snéöAkrezob <S gvögykK^Gsíeiikgxkíogsdhiúg hordtizos,
  2. 2. Az 1, igéüysmns szérGsíi gyögyszerészdi kijsziónény, and a gyógyszerészet lieg Gkígaöháté sö ,·. cltrátsó· .2 Az -.'2.> igénygönid*: Grands ;k-; -./vrest: gyógyszerészeti G-\/nmc:g . ahoi a stmt.-e-kre/doak y elkdee'ónnhez vált' kötésiértéke kiseblvmmt az la kép idő vegvölesssek vggy gYógyszéíészetrGg díögadhaiö sójának a cikkdesisGíhez vdsá kötési crick·::
  3. 4. Az előző igénypontok isiin ;dy ox szenna gyógyszerészeti készítmény. a írói 2,3 mg oö mcí,r t.re/ol a Gk lode Gri oben nincs megkötve. 3 Az előző ígényixéHék rGrrrdséke szesze; gyógyszerészeti készKtxéíöe sko; az i;· regien* vegyük-snek vagy győgyszetószetilégeHbgaönató sóiénak a eikkídesosídez való kötési értéke köü M és íxööb M‘! közötti.
  4. 6. Az eh >..-·> igénypssittök baroxdyske m—oli gyógyszerészetl készítmény gyógyszerként történé ailxslrnazásra,
  5. 7. Az i-é. igéoynöMok bémtdyike szerinti gyógyszerészeti készítmény olyan betegség kezdésében történő alksitnítzásrn, mndynéi ttéarokiöín ébeegóx antsgotóda javaik. G Gyégyszerészéö készömény alkalmazásra a 7. igénypont szeriéi, ahol a betegség, amdytsd neurokinin receptor agtngómst« javéi it. a hányás vagy az érzesieieGíéshöt való visszatérés javgása közül véltssz.ioU. ö. Gyógyszerészeti készítmény a Gaí mazasra s ód. ivdoynonrnk GrmtdyGe szcs ira, aboi n készítményt gnícincrdis unekensvai adjuk be,
HUE05702263A 2004-01-30 2005-01-17 Antimikrobiális tartósítószerek, béta-ciklodextrineket alkalmazó multidózisos formulációk eléréséhez folyékony dózisformák számára HUE034099T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54089704P 2004-01-30 2004-01-30

Publications (1)

Publication Number Publication Date
HUE034099T2 true HUE034099T2 (hu) 2018-01-29

Family

ID=34910697

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE05702263A HUE034099T2 (hu) 2004-01-30 2005-01-17 Antimikrobiális tartósítószerek, béta-ciklodextrineket alkalmazó multidózisos formulációk eléréséhez folyékony dózisformák számára

Country Status (25)

Country Link
US (1) US8183230B2 (hu)
EP (1) EP1713504B1 (hu)
JP (1) JP5021318B2 (hu)
KR (1) KR100834232B1 (hu)
CN (1) CN101090735A (hu)
AR (2) AR047469A1 (hu)
AU (1) AU2005216709B2 (hu)
BR (1) BRPI0506496B8 (hu)
CA (1) CA2554346C (hu)
CO (1) CO5700794A2 (hu)
CY (1) CY1119188T1 (hu)
DK (1) DK1713504T3 (hu)
ES (1) ES2638113T3 (hu)
HU (1) HUE034099T2 (hu)
IL (1) IL176676A0 (hu)
LT (1) LT1713504T (hu)
NO (1) NO20063858L (hu)
NZ (1) NZ548236A (hu)
PL (1) PL1713504T3 (hu)
PT (1) PT1713504T (hu)
RU (1) RU2332997C2 (hu)
SI (1) SI1713504T1 (hu)
TW (1) TW200524632A (hu)
WO (1) WO2005082416A2 (hu)
ZA (1) ZA200605148B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201506273PA (en) * 2011-11-29 2015-09-29 Jurox Pty Ltd Methods of preserving injectable pharmaceutical compositions comprising a cyclodextrin and a hydrophobic drug
AU2013273764B2 (en) * 2011-11-29 2016-05-05 Zoetis Services Llc Pharmaceutical compositions
MX2016000727A (es) * 2013-07-19 2016-04-13 Boehringer Ingelheim Vetmed Composicion farmaceutica acuosa liquida que contiene derivados de ciclodextrina eterificada con conservante.
NL2015865B1 (en) 2015-11-27 2017-06-13 Le Vet B V Maropitant Formulation.
MX2019012088A (es) 2017-04-10 2020-02-07 Chase Therapeutics Corp Combinacion de antagonista nk1 y metodo para tratar sinucleinopatias.
EP3645120A4 (en) 2017-06-30 2021-03-24 Chase Pharmaceuticals Corporation NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION
EP3923916A4 (en) * 2019-02-15 2022-12-21 Saol International Development Ltd. INJECTABLE PHENOL FORMULATIONS AND METHODS OF USE
EP3725298A1 (en) 2019-04-16 2020-10-21 Faes Farma, S.A. Stable and preserved pharmaceutical compositions of bilastine
CN112370451A (zh) * 2020-12-08 2021-02-19 河北科技大学 一种枸橼酸马罗匹坦包合物、注射液及制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5910510A (ja) * 1982-07-08 1984-01-20 Nippon Zenyaku Kogyo Kk 低刺激性チアムリン注射剤
JPS59152320A (ja) 1983-02-17 1984-08-31 Takeda Chem Ind Ltd 水性製剤
JPS6419737A (en) * 1987-07-15 1989-01-23 Hitachi Ltd Multilayer interconnection tape carrier
JPH039848A (ja) * 1989-06-06 1991-01-17 Canon Inc 液体噴射記録装置
SK390692A3 (en) 1991-05-31 1998-02-04 Pfizer Quinuclidine derivatives, preparation method thereof and use
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
ATE147385T1 (de) 1992-11-12 1997-01-15 Pfizer Chinuclidin derivat als substanz p antagonist
US5393762A (en) 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
CA2342797A1 (en) * 1998-09-02 2000-03-09 Allergan Sales, Inc. Preserved cyclodextrin-containing compositions
US6255320B1 (en) 1999-06-01 2001-07-03 Pfizer Inc. Polymorphs of a crystalline azo-bicyclo (2,2,2) octan-3-amine citrate and their pharmaceutical compositions
WO2001001955A1 (en) * 1999-07-02 2001-01-11 Janssen Pharmaceutica N.V. Nasal formulation of an antifungal
US7163681B2 (en) * 2000-08-07 2007-01-16 Centocor, Inc. Anti-integrin antibodies, compositions, methods and uses
JP4334229B2 (ja) * 2001-03-20 2009-09-30 サイデックス・ファーマシューティカルズ・インコーポレイテッド プロポフォール及びスルホアルキルエーテルシクロデキストリン含有製剤
US7034013B2 (en) 2001-03-20 2006-04-25 Cydex, Inc. Formulations containing propofol and a sulfoalkyl ether cyclodextrin
EP1411946A1 (en) * 2001-07-20 2004-04-28 Pfizer Products Inc. Use of nk-1 receptor antagonists to modify unwanted behavior in dogs, cats and horses
JP2005521691A (ja) 2002-02-22 2005-07-21 ファルマシア・コーポレーション シクロデキストリン化合物及び塩化セチルピリジニウムを含有する眼科用抗菌性薬物製剤
US6869939B2 (en) 2002-05-04 2005-03-22 Cydex, Inc. Formulations containing amiodarone and sulfoalkyl ether cyclodextrin
DE10228049A1 (de) 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US6861526B2 (en) 2002-10-16 2005-03-01 Pfizer Inc. Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
AU2005216707A1 (en) 2004-01-30 2005-09-09 Pfizer Products Inc. Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
RU2337685C2 (ru) 2004-01-30 2008-11-10 Пфайзер Продактс Инк. Антагонисты нейрокининового рецептора nk-1 для выхода из наркоза
ES2296131T3 (es) 2004-02-02 2008-04-16 Pfizer Products Incorporated Procedimiento para la preparacion de 1-(2s,3s)-2-bencidril-n-(5-terc-butil-2-metoxibencil)quinuclidin-3-amina.

Also Published As

Publication number Publication date
IL176676A0 (en) 2006-10-31
JP5021318B2 (ja) 2012-09-05
CA2554346C (en) 2009-11-17
WO2005082416A2 (en) 2005-09-09
KR100834232B1 (ko) 2008-05-30
BRPI0506496A8 (pt) 2017-11-14
EP1713504B1 (en) 2017-06-07
ES2638113T3 (es) 2017-10-18
AU2005216709A1 (en) 2005-09-09
BRPI0506496B8 (pt) 2022-09-20
SI1713504T1 (sl) 2017-10-30
BRPI0506496A (pt) 2007-02-13
RU2332997C2 (ru) 2008-09-10
CA2554346A1 (en) 2005-09-09
PL1713504T3 (pl) 2017-12-29
AR109357A2 (es) 2018-11-21
AR047469A1 (es) 2006-01-18
NZ548236A (en) 2010-02-26
CY1119188T1 (el) 2018-02-14
NO20063858L (no) 2006-10-19
ZA200605148B (en) 2007-10-31
BRPI0506496B1 (pt) 2018-10-09
CN101090735A (zh) 2007-12-19
CO5700794A2 (es) 2006-11-30
JP2007519703A (ja) 2007-07-19
TW200524632A (en) 2005-08-01
KR20060128973A (ko) 2006-12-14
WO2005082416A3 (en) 2006-07-27
PT1713504T (pt) 2017-08-29
RU2006127422A (ru) 2008-03-10
AU2005216709B2 (en) 2008-02-07
US8183230B2 (en) 2012-05-22
LT1713504T (lt) 2017-09-11
EP1713504A2 (en) 2006-10-25
US20070155697A1 (en) 2007-07-05
DK1713504T3 (en) 2017-08-07

Similar Documents

Publication Publication Date Title
DK1713504T3 (en) Antimicrobial preservatives to obtain multi-dose formulations using beta-cyclodextrins for liquid dosage forms
US20220265636A1 (en) Antimicrobial compositions
US7034013B2 (en) Formulations containing propofol and a sulfoalkyl ether cyclodextrin
US20030055023A1 (en) Formulations containing etomidate and a sulfoalkyl ether cyclodextrin
US11123357B2 (en) Methods and compositions for treating oral mucositis
US20070129328A1 (en) Pharmaceutical compositions of neurokinin receptor antagonists and cyclodextrin and methods for improved injection site toleration
US20190314336A1 (en) Parenteral liquid preparation comprising carbamate compound
MXPA06008032A (en) Antimicrobial preservatives to achieve multi-dose formulation using beta-cyclodextrins for liquid dosage forms
US20170368055A1 (en) Methods for treating infections